Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors.
Kaysia LudfordWon Jin HoJane V ThomasKanwal P S RaghavMariela Blum MurphyNicole D FlemingMichael S LeeBrandon G SmagloY Nancy YouMatthew M TillmanCarlos Kamiya-MatsuokaSelvi ThirumurthiCraig MessickBenny JohnsonEduardo VilarArvind N DasariSarah M ShinAlexei HernandezXuan YuanHongqui YangWai Chin FooWei QiaoDipen Maheshbhai MaruEdmund S KopetzMichael James OvermanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Neoadjuvant pembrolizumab in dMMR/MSI-H cancers is safe and resulted in high rates of pathologic, radiographic, and endoscopic response, which has implications for organ-sparing strategies.